C9175 – Injection, treosulfan, 50 mg
HCPCS Level II code · C codes: Outpatient PPS (Hospital Outpatient)
HCPCS codeC9175
- Long description
- Injection, treosulfan, 50 mg
- Short description
- Inj, treosulfan, 50 mg
- Pricing indicator
53Statute- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- July 1, 2025
- Last change
- October 1, 2025 – No change
- Termination date
- September 30, 2025
Frequently asked questions
What is HCPCS code C9175?
C9175 is a HCPCS Level II code for injection, treosulfan, 50 mg. It was discontinued on September 30, 2025.
Does Medicare cover C9175?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby C codes
- C9167 – Injection, adamts13, recombinant-krhn, 10 iu
- C9168 – Injection, mirikizumab-mrkz, 1 mg
- C9169 – Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
- C9170 – Injection, tarlatamab-dlle, 1 mg
- C9171 – Injection, pegulicianine, 1 mg
- C9172 – Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
- C9173 – Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
- C9174 – Injection, datopotamab deruxtecan-dlnk, 1 mg
- C9176 – Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study dose
- C9248 – Injection, clevidipine butyrate, 1 mg
- C9250 – Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml
- C9254 – Injection, lacosamide, 1 mg
- C9257 – Injection, bevacizumab, 0.25 mg
- C9275 – Injection, hexaminolevulinate hydrochloride, 100 mg, per study dose
- C9285 – Lidocaine 70 mg/tetracaine 70 mg, per patch
- C9290 – Injection, bupivacaine liposome, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.